NVAX Q4 2025 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$147M+66.6% YoY

Gross Profit

$122M82.9% margin

Operating Income

$21M14.3% margin

Net Income

$18M11.9% margin

EPS (Diluted)

$0.11

QoQ Revenue Growth

+108.9%

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$42M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$1.3B

Stockholders' Equity

-$128M

Cash & Equivalents

$241M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$147M	$88M	+66.6%
Gross Profit	$122M	$52M	+136.1%
Operating Income	$21M	-$131M	+116.0%
Net Income	$18M	-$81M	+121.6%

Revenue Segments

Product

$661M94%

Supply Sales

$20M3%

Nuvaxovid Sales

$20M3%

Geographic Segments

UNITED STATES

$111M76%

Rest of the World

$33M22%

Europe

$3M2%